RxDoctor Payments Data

Rebecca Nicholson

Family · Knoxville, TNNPI 1871053736

Payments from drug & device makers

$2,333in general payments, 2019–2025

Across 74 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$669
  • Johnson & Johnson$417
  • Amgen$388
  • E.r. Squibb & Sons, L.L.C.$231
  • Pfizer$135
  • Esperion Therapeutics, Inc.$117
  • plus $377 from 10 others

What the payments were for

  • Food & beverage$2,32199%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,333 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$54,819
Medicare patients
347
Services billed
776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban284$311,146
EntrestoSacubitril/Valsartan90$105,909
XareltoRivaroxaban86$78,425
BrilintaTicagrelor61$43,759
Repatha SureclickEvolocumab39$25,647
Repatha SyringeEvolocumab15$12,633
JardianceEmpagliflozin11$10,490
Ranolazine ErRanolazine43$4,314
ClopidogrelClopidogrel Bisulfate320$3,312
Atorvastatin Calcium300$2,624
Losartan Potassium267$2,500
Metoprolol Succinate140$2,000
Nitroglycerin84$1,755
Rosuvastatin Calcium155$1,594
Carvedilol234$1,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$311,146284 claims
NovartisEntresto$42$105,90990 claims
Johnson & JohnsonXarelto$417$78,42586 claims
Boehringer IngelheimJardiance$102$10,49011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →